Michael Okunewitch
Stock Analyst at Maxim Group
(0.72)
# 3,720
Out of 5,090 analysts
30
Total ratings
26.92%
Success rate
-10.21%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Downgrades: Hold | n/a | $0.30 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $1.59 | +528.93% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $1.12 | +435.76% | 3 | Sep 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $2.26 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $1.98 | +1,667.68% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.75 | +152.63% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $2.48 | +1,029.03% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.16 | +1,106.90% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.72 | +74.42% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.22 | +227.87% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.26 | +4,450.63% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.62 | +875.61% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $1.06 | +1,032.08% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.37 | +912.66% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.03 | +786.70% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.25 | +89,900.00% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $17.68 | +41.40% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.11 | +440.54% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.32 | +478.70% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.18 | +8,374.58% | 1 | Nov 30, 2021 |
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.30
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.59
Upside: +528.93%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $1.12
Upside: +435.76%
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.26
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $1.98
Upside: +1,667.68%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.75
Upside: +152.63%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $2.48
Upside: +1,029.03%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.16
Upside: +1,106.90%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.72
Upside: +74.42%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.22
Upside: +227.87%
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.26
Upside: +4,450.63%
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.62
Upside: +875.61%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $1.06
Upside: +1,032.08%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $2.37
Upside: +912.66%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.03
Upside: +786.70%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.25
Upside: +89,900.00%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $17.68
Upside: +41.40%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.11
Upside: +440.54%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $4.32
Upside: +478.70%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.18
Upside: +8,374.58%